Literature DB >> 10639276

Molecular recognition of modified adenine nucleotides by the P2Y(1)-receptor. 1. A synthetic, biochemical, and NMR approach.

E Halbfinger1, D T Major, M Ritzmann, J Ubl, G Reiser, J L Boyer, K T Harden, B Fischer.   

Abstract

The remarkably high potencies of 2-thioether-adenine nucleotides regarding the activation of the P2Y(1)-receptor (P2Y(1)-R) in turkey erythrocyte membranes represent some of the largest substitution-promoted increases in potencies over that of a natural receptor ligand. This paper describes the investigation regarding the origin of the high potency of these P2Y(1)-R ligands over that of ATP. For this study, an integrated approach was employed combining the synthesis of new ATP analogues, their biochemical evaluation, and their SAR analysis involving NMR experiments and theoretical calculations. These experiments and calculations were performed to elucidate the conformation and to evaluate the electronic nature of the investigated P2Y(1)-R ligands. ATP analogues synthesized included derivatives where C2 or C8 positions were substituted with electron-donating groups such as ethers, thioethers, or amines. The compounds were tested for their potency to induce P2Y(1)-R-mediated activation of phospholipase C in turkey erythrocytes and Ca(2+) response in rat astrocytes. 8-Substituted ATP and AMP derivatives had little or no effect on phospholipase C or on calcium levels, whereas the corresponding 2-substituted ATP analogues potently increased the levels of inositol phosphates and ¿Ca(2+)(i). AMP analogues were ineffective except for 2-butylthio-AMP which induced a small Ca(2+) response. P2Y(1)-R activity of these compounds was demonstrated by testing these ligands also on NG108-15 neuroblastoma x glioma hybrid cells. NMR data together with theoretical calculations imply that steric, rather than electronic, effects play a major role in ligand binding to the P2Y(1)-R. Hydrophobic interactions and H-bonds of the C2 substituent appear to be important determinants of a P2Y(1)-R ligand affinity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10639276     DOI: 10.1021/jm990156d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist.

Authors:  Shir Yelovitch; Haim M Barr; Jean Camden; Gary A Weisman; Ela Shai; David Varon; Bilha Fischer
Journal:  J Med Chem       Date:  2012-08-20       Impact factor: 7.446

2.  Nucleotides and inorganic phosphates as potential antioxidants.

Authors:  Yael Richter; Bilha Fischer
Journal:  J Biol Inorg Chem       Date:  2006-08-01       Impact factor: 3.358

3.  Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(α or γ)-thio-(α,β- or β,γ)-methylenetriphosphate scaffold.

Authors:  Yael Nadel; Joanna Lecka; Yocheved Gilad; Gal Ben-David; Daniel Förster; Georg Reiser; Sarah Kenigsberg; Jean Camden; Gary A Weisman; Hanoch Senderowitz; Jean Sévigny; Bilha Fischer
Journal:  J Med Chem       Date:  2014-05-30       Impact factor: 7.446

4.  Pharmacochemistry of the platelet purinergic receptors.

Authors:  Kenneth A Jacobson; Francesca Deflorian; Shilpi Mishra; Stefano Costanzi
Journal:  Purinergic Signal       Date:  2011-02-18       Impact factor: 3.765

5.  Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate.

Authors:  Andrei A Ivanov; Hyojin Ko; Liesbet Cosyn; Savitri Maddileti; Pedro Besada; Ingrid Fricks; Stefano Costanzi; T Kendall Harden; Serge Van Calenbergh; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2007-02-16       Impact factor: 7.446

6.  8-BuS-ATP derivatives as specific NTPDase1 inhibitors.

Authors:  Joanna Lecka; Irina Gillerman; Michel Fausther; Mabrouka Salem; Mercedes N Munkonda; Jean-Philippe Brosseau; Christine Cadot; Mireia Martín-Satué; Pedro d'Orléans-Juste; Eric Rousseau; Donald Poirier; Beat Künzli; Bilha Fischer; Jean Sévigny
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

7.  Subtype specific internalization of P2Y1 and P2Y2 receptors induced by novel adenosine 5'-O-(1-boranotriphosphate) derivatives.

Authors:  M E Tulapurkar; W Laubinger; V Nahum; B Fischer; G Reiser
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

Review 8.  Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).

Authors:  Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2009-04-30       Impact factor: 4.774

9.  New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.

Authors:  Ivan B Yanachkov; Hung Chang; Milka I Yanachkova; Edward J Dix; Michelle A Berny-Lang; Thomas Gremmel; Alan D Michelson; George E Wright; Andrew L Frelinger
Journal:  Eur J Med Chem       Date:  2015-11-09       Impact factor: 6.514

10.  Development of selective agonists and antagonists of P2Y receptors.

Authors:  Kenneth A Jacobson; Andrei A Ivanov; Sonia de Castro; T Kendall Harden; Hyojin Ko
Journal:  Purinergic Signal       Date:  2008-07-04       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.